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Takeshi Iwasaki1, Satoshi Kuwamoto1, Masako Kato1, Keiko Nagata1, Kazuhiko Hayashi1, Shinsaku Imashuku5,
Jean Gogusev6, Francis Jaubert7, Takashi Oka8 and Tadashi Yoshino8Abstract
Background: Langerhans cell histiocytosis (LCH) is a proliferative disorder in which abnormal Langerhans cell (LC)-like
cells (LCH cells) intermingle with inflammatory cells. Whether LCH is reactive or neoplastic remains a controversial
matter. We recently described Merkel cell polyomavirus (MCPyV) as a possible causative agent of LCH and proposed
interleukin-1 loop model: LCH is a reactive disorder with an underlying oncogenic potential and we now propose to
test this theory by looking for acute markers of inflammation. We detected MCPyV-DNA in the peripheral blood cells of
patients with high-risk organ-type (LCH-risk organ (RO) (+)) but not those with non–high-risk organ-type LCH (LCH-RO
(−)); this difference was significant. LCH-RO (−) is further classified by its involvement of either a single organ system
(SS-LCH) or multiple organ systems (MS-LCH). In patients with LCH-RO (−), MCPyV-DNA sequences were present in LCH
tissues, and significant differences were observed between LCH tissues and control tissues associated with conditions
such as dermatopathic lymphadenopathy and reactive lymphoid hyperplasia. Although MCPyV causes subclinical
infection in nearly all people and 22 % of healthy adults will harbor MCPyV in their buffy coats, circulating monocytes
could serve as MCPyV reservoirs and cause disseminated skin lesions.
Methods: Plasma sample from 12 patients with LCH-RO (−) (5 MS-LCH and 7 SS-LCH) and 5 non-LCH patients were
analyzed by peptidomics. Mass spectrometry (MS) spectra were acquired and peptides exhibiting quantitative
differences between MS-LCH and SS-LCH patients were targeted.
Results: One new candidate biomarker, m/z 3145 was selected and identified after obtaining a MS/MS fragmentation
pattern using liquid chromatography-MS/MS. This peak was identified as a proteolytic fragment derived from inter-
alpha-trypsin inhibitor heavy chain 4 (ITIH4, [PDB: Q14624]).
Conclusions: Peptidomics of LCH have revealed that the level of acute-phase ITIH4 distinguishes MS-LCH-RO (−)
from SS-LCH-RO (−). Acute-phase proteins serve non-specific, physiological immune functions within the innate
immune system. LCH may be a reactive disorder with both underlying neoplastic potential of antigen presenting
cells harboring BRAF mutations and hyper-immunity of other inflammatory cells against MCPyV infection. Among
LCH-RO (−), MCPyV-DNA sequences were present in both MS-LCH tissues and SS-LCH tissues without significant
differences. ITIH4 may show that LCH activity or LCH subtypes correlates with the systemic or localized reactions
of MCPyV infection.
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LCH is a proliferative disorder in which abnormal Lang-
erhans cell (LC)-like cells (LCH cells) intermingle with
inflammatory cells [1, 2]. The appearance of LCH lesions
under the microscope, which commonly contain only a
small number of abnormal immune LCH cells sur-
rounded by many normal immune cells initially led to
questions about LCH as a cancer or immune disorder
[3]. For decades, it was thought that the disease is a re-
active disorder rather than a neoplastic process [4]. The
discovery of the B-Rapidly Accelerated Fibrosarcoma
gene (BRAF) [GenBank: G_007873] mutation in 2010 [5]
gave new insights into LCH pathogenesis. Clonality [6,
7] and BRAF mutation [5] suggest neoplasm [1], whereas
granuloma formation [8] with spontaneous regression
[1], and hypercytokinemia [1, 9] indicate a reactive
process. BRAF mutation does not distinguish LCH sub-
classes, which vary from self-healing to lethal [5]. Re-
cently, there has been much discussion concerning
whether or not LCH is considered a cancer. This discus-
sion started when a recent change to patient information
about LCH on the National Cancer Institute’s website
[10] stated, “LCH is a type of cancer that can damage
tissue or cause lesions to form in one or more places in
the body.” On the contrary, the Histiocyte Society Scien-
tific Committee [3] stated “All cancers are considered
neoplasias, but not all neoplasias are cancerous.” At
present time no clear consensus seem to have been
reached regarding whether LCH is reactive or neoplastic
[1] and whether LCH is cancerous [10] or not [3].
Very recently, we [11] propose a new model for LCH
pathogenesis in which the disease is a reactive disorder
with underlying neoplastic potential. In other words,
LCH is an inflammatory process that is prolonged by
BRAF mutation (interleukin (IL)-1 loop model) [11].Table 1 Clinical manifestations, treatment, outcome and proposed r
on both our and others’ data
Classification Prevalence
(approximate)
Clinical
manifestaions
Treatm
Present Former
LCH-
RO (+)
MSa Letterer–Siwe
disease
10 % Serious anemia,
Thrombocytopenia
Multi-a
chemo
Salvag
LCH-
RO (−)
MS Hand–Schüller–
Christian disease
20 % Bone pain, Skin
rash
Multi-a
chemo
SS Eosinophilic
granuloma
70 % Asymptomatic or
Bone pain
Wait-a
Chemo
ITIH4 inter-alpha-trypsin inhibitor heavy chain 4, LCH Langerhans cell histiocytosis, L
and bone marrow), LCH-RO (−) LCH with no involvement of high-risk organ, MCPyV
NA not available
aNearly all LCH-risk organ (RO) (+) type is MS-LCH-RO (+), although SS-LCH-RO (+) t
bLocalized LCH may resolve spontaneously [2], which might be related to oncogene
network [46]. We detected MCPyV-DNA in the peripheral blood mononuclear cells (
difference was significant. In patients with LCH-RO (−), MCPyV-DNA sequences wereThe liver, spleen, and bone marrow are considered
high-risk organs for LCH [12, 13]. LCH is classified as
involving at least one [LCH-risk organ (RO) (+)] or no
high-risk organs [LCH-RO (−)] [12]. LCH-RO (−) pre-
sents as multisystem (MS-LCH) or single-system disease
(SS-LCH) [14]. Nearly all LCH-RO (+) is MS-LCH-RO
(+), although SS-LCH-RO (+) has been reported [15,
16]. We [17] reported Merkel cell polyomavirus
(MCPyV)-DNA in the peripheral blood mononuclear
cells (PBMC) of patients with LCH-RO (+), whereas
MCPyV-DNA was significantly restricted to lesional
LCH cells in patients with LCH-RO (−) and so we pre-
dict that acute phase markers are related to inflamma-
tory activities of LCH (Table 1) [2]. Berres et al. [18]
reported that circulating CD11c + and CD14+ cellular
fractions in patients with LCH-RO (+) harbored BRAF
mutations; the mutation was restricted to LCH cells in
patients with LCH-RO (−).
The clinical course of LCH varies quite widely depend-
ing on the extent of organ involvement [2] and relation-
ship between LCH subtypes and MCPyV and mutations
are shown roughly in Table 1. Treatment of LCH should
be planned according to the clinical presentation and
the extent of organ involvement [2]. In LCH-RO (+), in
which circulating precursor LCH cells as a reservoirs for
MCPyV may relate to involving high risk organ ((extra-
medullary) hematopoietic organ) (Table 1), main aims of
treatment are to increase survive and to reduce the inci-
dence of late sequelae [2]. In LCH-RO (−), treatment
differs widely from a wait-and-see approach for SS-LCH
to systemic chemotherapy for MS-LCH [2]. However,
the clinical significance of MCPyV infection and BRAF
mutation has not been settled because they occur
equally as frequently in MS-LCH-RO (−) and SS-LCH-
RO (−) (Table 1) [5].elationship between LCH classification, MCPyV and ITIH4 based
ent Outcome MCPyV-DNA Mutations ITIH4
PBMC LCH
tissue
PBMC LCH
tissue
Plasma
gent
therapy and
e therapy
Mortality
rates: 16–
38 %
+ NA + + NA
gent
therapy
Excellent
survival rate
- + - + high
nd-see strategyb or
therapy
Excellent
prognosis
+ + low
CH-RO (+) LCH with involvement of at least one high-risk organ (spleen, liver,
Merkel cell polyomavirus, MS-LCH multisystem LCH, SS-LCH single-system LCH,
ype has been reported [15, 16]
-induced senescence [45] relayed by interleukin-dependent inflammatory
PBMC) of patients with LCH-RO (+) but not those with LCH-RO (−); this
present in LCH tissues
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LCH. In many cases, LCH presents with nonspecific in-
flammatory signs that arise from chronic inflammation
[2], although comprehensive analysis of serum levels of
cytokines/chemokines and growth factors in pediatric
patients with LCH was done [19].
As mentioned above, we predict that acute phase
markers are related to inflammatory activities of LCH
subtypes (Table 1) and demonstrate, via plasma peptido-
mics, that acute-phase ITIH4 (inter-alpha-trypsin inhibi-
tor heavy chain 4) levels can distinguish MS-LCH-RO
(−) from SS-LCH-RO (−) in this paper.
Methods
Patients and plasma samples
This study was approved by the Institutional Review
Boards of Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences,
Okayama, Japan; Faculty of Medicine, Tottori University,
Tottori, Japan; and Jichi Medical University School of
Medicine, Tochigi, Japan. After obtaining written in-
formed consent, plasma samples were obtained from af-
fected patients in the Japan LCH Study Group registry
between 2002 and 2009 and Jichi Medical University
School of Medicine.
Plasma sample aliquots from 12 patients with LCH-
RO (−) (5 MS-LCH and 7 SS-LCH) were stored at −80 °
C until further analysis. For confirmative studies, plasma
samples were obtained from 5 non-LCH patients at the
Division of Pediatrics and Perinatology, Faculty of Medi-
cine, Tottori University.
Whole-plasma peptidome analyses (Peptidomics)
The whole-plasma peptidome was directly analyzed via a
lithium dodecyl sulfate (LDS)-based 1-D polyacrylamide
gel electrophoresis (PAGE)/matrix-assisted laser desorp-
tion/ionization (MALDI) mass spectrometry (MS)-based
rapid quantitative method using BLOTCHIP® (Protosera,
Amagasaki, Japan) [20]: plasma samples were treated
with NuPAGE LDS sample buffer (Life Technologies,
Carlsbad, CA, USA), heated for 10 min at 70 °C, and ap-
plied to NuPAGE Novex Bis-Tris Mini Gels 4–12 % (Life
Technologies, No gel is shown). After 1-D PAGE, slab
gels were sliced into gel strips; two strips were placed on
each chip. Peptides contained in the gel strips were elec-
troblotted onto the chip using an XCell IITM Blot
Module (Life Technologies). MALDI matrix-cyano-4-
hydroxycinnamic acid (CHCA) (Sigma-Aldrich, MO,
USA) was applied to each BLOTCHIP® using an auto-
matic matrix-dispensing machine (Protosera).
MS spectra were acquired on an UltraFlex II MALDI-
time of flight (TOF)/TOF (Bruker Daltonics, Billerica,
MA, USA) interfaced with flexAnalysis version 2.4 soft-
ware (Bruker Daltonics) as previously described [20]under the following conditions: laser intensity, 28–37 %;
detector voltage, 1685 V; suppression, 500, fuzzy mode;
and molecular mass range, m/z 1000–30,000.
All plasma sample measurements were repeated four
times. The resulting 29 MS spectra per each measure-
ment were combined using flexAnalysis version 2.4 to
generate an integrated MS spectrum in the molecular
mass range of m/z 1000–20,000. The mean relative peak
intensities, normalized to a total ion current of m/z be-
tween 1000 and 6000, were expressed as arbitrary units
(a.u.) [21].
Measurement of monoisotopic masses on BLOTCHIP®
Monoisotopic masses of statistically significant peaks
were recorded in reflector mode on an Ultraflex II in-
strument (Bruker Daltonics).
Purification and MS/MS identification of peptides
Plasma samples were selected for peptide purification as
follows: peptides exhibiting quantitative differences be-
tween MS-LCH and SS-LCH patients were targeted
based on the statistical analysis of MS data. Blood sam-
ples containing the highest target peptide concentrations
were used by Protosera as sources for further identifica-
tion studies.
MS/MS spectra of the target peptides were obtained
via liquid chromatography (LC)-MS/MS (Q Exactive,
Thermo Fisher Scientific K. K., Yokohama, Japan); frag-
mentation data were applied to a “nonredundant” hu-
man database search (both NCBInr and Swiss-Prot) via
the MASCOT MS/MS ions search program version 2.1.0
(Matrix Science, Boston, MA, USA) in Biotools software
(Bruker Daltonics).
Statistical analysis
All statistical MS data analyses were conducted using
ClinPro Tools version 2.2 (Bruker Daltonics) [22]. Peak
heights exhibiting significant statistical differences be-
tween two groups (MS-LCH versus SS-LCH) were se-
lected. MS data intensity comparisons between patients
with MS-LCH and SS-LCH were performed using Stu-
dent’s t-test. Differences between values were considered
statistically significant at P < 0.05.
Results and discussion
Clinical profiles of patients in this study with LCH and
non-LCH are summarized in Table 2. Plasma samples
from LCH (n = 12) and non-LCH patients (n = 5) were
subjected to BLOTCHIP® followed by MS analysis. Sub-
sequent differential profiling analyses of the two sample
sets were performed based on data obtained from the
MS analysis. Quantitative differences in peptide peaks
between the groups were noticeable primarily in the
2000–6500 m/z range. Statistical analysis indicated that
Table 3 Receiver operating characteristic (ROC) analysis of 32
peaks
m/z SN SP Cutoff AUC
1467 100 57 28,182 0.73
1796 43 100 6693 0.71
1988 100 57 7096 0.78
2013 86 100 8899 0.94
2211 100 43 13,844 0.69
2273 57 100 808 0.84
2555 100 57 18,160 0.67
2601 86 100 2858 0.96
2662a 86 43 216 0.63
2727 86 86 3612 0.82
2810 100 43 11,023 0.59
2962a 86 57 8557 0.69
3145 86 71 3710 0.73
3159 100 43 14,491 0.71
3291 86 86 1880 0.84
3354 100 57 3537 0.80
3509 100 71 6796 0.84
3522 100 71 4945 0.84
3686 86 86 1603 0.86
3953a 71 86 6547 0.76
3973 100 71 15,117 0.82
3990 86 71 6868 0.82
4154 43 100 15,100 0.73
4186 71 86 15,088 0.73
4301 100 71 16,035 0.84
4317 100 100 26,194 1.00
4840a 100 57 29,114 0.73
5586a 71 71 3706 0.73
7773a 100 29 24,831 0.57
8646 71 100 20,684 0.90
15217a 86 71 1720 0.80
17492a 71 71 8478 0.65
SN sensitivity, SP specificity, AUC area under the curve, m/z higher intensity
marker in MS-LCH-RO (−), m/za higher intensity marker in SS-LCH-RO (−)
Table 2 Clinical characteristics of patients with LCH-RO (−) or
non-LCH
Patients Age Sex Diagnosis
(subtype)
Distribution of LCH
lesions
L1 3 years
0 month
M MS-LCH Parietal bone, Ear canal,
Lung
L2 7 years
0 month
F MS-LCH Bone, Skin, Pituitary
gland
L3 4 years
10 months
M MS-LCH Skin, Bone, Pituitary
gland, CNS
L4 1 year
0 month
M MS-LCH Bone, Orbit
L5 11 years
4 months
F MS-LCH Bone, Pituitary gland
L6 11 years
11 months
M SS-LCH Bone
L7 4 years
11 months
F SS-LCH Bone
L8 9 years
0 month
M SS-LCH Bone
L9 6 years
0 month
M SS-LCH Bone
L10 1 years
0 month
F SS-LCH Skin
L11 4 years
4 months
F SS-LCH Bone
L12 1 years
3 months
M SS-LCH Bone
C1 2 years
4 months
F Toxicoderma −
C2 2 years
3 months
M Kawasaki
disease
−
C3 10 years
0 month
F SLE −
C4 2 years
3 months
M ITP −
C5 1 year
11 months
M Kawasaki
disease
−
The median age of the MS-LCH patients (n = 5) was 4 years, 10 months (range:
1 year, 0 months–11 years, 4 months). The median age of the SS-LCH patients
(n = 7) was 4 years, 11 months (range: 1 year, 0 months–11 years, 11 months).
The median age of non-LCH patients (n = 5) was 2 years, 3 months (range: 1 year,
3 months–10 years, 0 months). Abbreviations: CNS central nervous system, ITP
idiopathic thrombocytopenic purpura, LCH Langerhans cell histiocytosis, LCH-RO
(−) LCH with no involvement of high-risk organ (spleen, liver, and bone marrow),
MS-LCH multisystem LCH, SLE systemic lupus erythematosus, SS-LCH
single-system LCH
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and SS-LCH patients at an average m/z of <6000 (Table 3
and Fig. 1a).
Three new candidate biomarkers, m/z 2555, m/z 2962
and m/z 3145 (Fig. 1b), differed quantitatively between
MS-LCH and SS-LCH patients and were selected.
Among three peptides, only m/z 3145 was identified
after obtaining a MS/MS fragmentation pattern using
LC-MS/MS (Fig. 1c). This peak was identified as a pro-
teolytic fragment derived from ITIH4, ([PDB: Q14624];Integrated into UniProtKB/Swiss-Prot: July 15, 1998)
(Fig. 1d).
ITIH4 is an acute-phase-related protein [23] and po-
tential new biomarker for distinguishing MS-LCH and
SS-LCH (Table 3 and Fig. 1e). Acute-phase proteins
serve non-specific, physiological immune functions
within the innate immune system [24]. ITIH4 has been
detected in animals during experimental bacterial and
viral infections [25].
MCPyV causes subclinical infection in nearly all
people [26]. Although 22 % of healthy adults will harbor
Fig. 1 (See legend on next page.)
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Fig. 1 Plasma peptidomics of patients with LCH-RO (−). (a) Blue and red lines indicate integrated MS spectra of each MS-LCH and SS-LCH sample,
respectively. All plasma sample measurements were repeated four times. The resulting 29 MS spectra per each measurement were combined using
flexAnalysis version 2.4 to generate an integrated MS spectrum. Statistical analysis indicated that 32 peptide peaks differed significantly between MS-
LCH and SS-LCH patients at an average m/z of <6000. Peaks (arbitrary unit [a.u.]) in the range of m/z 2000–5000, which contains m/z 3145 (arrow), are
shown. (b) Blue and red lines indicate each MS spectrum of MS-LCH and SS-LCH samples, respectively. Peaks in the range of m/z 3127–3162, which
contains m/z 3145 (arrow), are shown. (c) Blood samples containing the highest concentrations of the target peptide m/z 3145 were used for further
identification studies. MS/MS spectra of the target peptides were obtained via LC-MS/MS (Q Exactive). The MS/MS fragmentation data of m/z 3145
were applied to a “nonredundant” human database search (both NCBInr and Swiss-Prot) using MASCOT MS/MS ions search program version 2.1.0 in
Biotools software. MS/MS fragmentations of NFRPGVLSSRQLGLPGPPDVPDHAAYHPF, a peptide found in inter-alpha-trypsin inhibitor heavy chain 4
(ITIH4, [PDB: Q14624]), were detected (ion score: 89; expect: 0.00062). Y-axis: relative intensity. (d) A profile summary of peptide fragment m/z 3145
(ITIH4). The amino acid sequence is presented according to the Paris Convention guidelines for peptidomics data presentation. (e) Peptidomics data
indicating the intensities of m/z 3145 (ITIH4 fragment) in MS-LCH, SS-LCH, and non-LCH plasma samples were plotted as box-whisker plots. For the
MS-LCH, SS-LCH, and non-LCH samples, the median intensities are 15710.537, 2412.950, and 14157.62538, lower quartiles are 4081.623, 1583.592, and
12148.52916, and upper quartiles are 17688.457, 3635.496, and 20523.77099, respectively. P values (Student’s t-test) are also indicated (An asterisk means
P > 0.05. A double asterisk means P < 0.05. A triple asterisk means P < 0.01). LCH-RO (−), LCH with no involvement of high-risk organ (spleen, liver, and
bone marrow)
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could serve as MCPyV reservoirs and cause dissemi-
nated skin lesions [28]. Martel-Jantin et al. [29] reported
seroprevalence rate of MCPyV antibodies of children
12 months or younger (49/105) in Cameroon and
pointed out the presence of maternal antibodies in very
young children. Their data indicated that MCPyV infec-
tions mostly occurred during early childhood, after the
disappearance of specific maternal antibodies [29]. On
the contrary Tolstov et al. [30] reported seroprevalence
rate of MCPyV antibodies of children of 1 year or youn-
ger (0/6) in patients with LCH. We [17] identified a rela-
tionship between LCH and MCPyV. MCPyV-DNA in
PBMC correlated with LCH-RO (+) [17]. Among pa-
tients with LCH-RO (−) (MS-LCH and SS-LCH),
MCPyV-DNA was restricted to lesional LCH cells [17],
and we predict that primary MCPyV infection may influ-
ence the LCH subtype involving cells in an early-
activated state [4].
Generally, no response is observed after secondary
viral infection [25]. Primary respiratory syncytial virus
infection at 6 months or younger often induces severe
disease [31], although nearly all children are infected by
2–3 years of age [32]. Primary Epstein-Barr virus and
cytomegalovirus infections in elderly individuals cause a
severe condition called infectious mononucleosis; again,
nearly all children are infected with these viruses [33].
Although no response is observed after MCPyV infec-
tion [26, 27], Kumar et al. [34], however, found that
MCPyV-specific T helper cells (in vitro model of a sec-
ondary infection) secrete several cytokines, including IL-
10. IL-10 is an anti-inflammatory cytokine and is one of
cytokines produced in LCH [2, 35]. ITIH4 production is
up-regulated by IL-6 [23], which is known produced in
LCH [2], one of the mediators coordinating the interface
between adaptive and innate immunity [36], and might
be a target for the therapy [37]. Innate immune function
between newborns and elderly is extremely different andlarge quantities of IL-6 after stimulation of receptors,
such as Toll like receptor, by term newborns are indi-
cated [38]. In LCH, MCPyV infection may induce hyper-
immunity in both LCH cells [11] and other inflamma-
tory cells [1, 2]. Increased mRNA expression of BRAF,
which was proven in MCPyV-positive non-small cell
lung cancer [39], may also influence BRAF mutated pre-
cursor LCH cells.Conclusions
LCH is a proliferative disorder in which LCH cells inter-
mingle with inflammatory cells [1, 2]. Very recently, we
[11] proposed a new model for LCH pathogenesis in
which the disease is a reactive disorder with both under-
lying neoplastic potential of LCH cells and other inflam-
matory cells such as T cells, macrophages, and
eosinophils. In other words, LCH is an inflammatory
process that is prolonged by mutations of antigen present-
ing cells (IL-1 loop model). The other inflammatory cells
may be informed and instigated by the mutated antigen
presenting cells. We tested this theory by examining the
abundance of a well-established acute phase marker
ITIH4. The presence of the acute phase markers observed
is compatible with our proposed theory. Cytokine storm is
one of characteristics of LCH and the fact that serum
levels of some cytokines but not LCH histology, which is
so uniform that pathologists cannot determine whether a
given biopsy originates from a patient with LCH-RO (+)
or LCH-RO (−) [40], deeply correlate to LCH activity and
LCH subtypes [19, 41–44] explicitly reach this inflamma-
tory reactive model in LCH.
Peptidomics suggests that the systemic or localized re-
action against MCPyV may influence LCH activity or
subtypes. Primary infection without maternal immuno-
globulins against MCPyV [29, 30] may influence LCH
activity or subtypes. In the aspect of data validation, an
orthogonal quantitation method has to be conducted,
Murakami et al. Clinical Proteomics  (2015) 12:16 Page 7 of 8e.g., an ELISA for absolute quantification of ITIH4 in
the future.
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